MedTrace Logo

A Study of the Efficacy and Safety of Supaglutide in Healthy Participants

NCT03745885 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2021-09-17

No results posted yet for this study

Summary

This study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the investigational drug Supaglutide proposed dosing once (or twice) weekly in Chinese healthy subjects.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Supaglutide injection

Administered SC in the Supaglutide arms.

DRUG

Placebo

Administered SC in the placebo arms and to maintain the blind in the Supaglutide injection arms.

Sponsors & Collaborators

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    collaborator OTHER

  • Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-12-04
Primary Completion
2019-06-10
Completion
2019-12-13

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03745885 on ClinicalTrials.gov